Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ractopamine is a synthetic phenethanolamine and β-adrenergic agonist used as a feed additive in livestock to promote leanness and improve feed conversion efficiency. It is primarily administered to swine (as Paylean), cattle (as Optaflexx), and turkeys (as Topmax) during the final weeks before slaughter. Ractopamine acts as an agonist at β1- and β2-adrenergic receptors as well as trace amine-associated receptor 1 (TAAR1), leading to increased protein synthesis in muscle tissue, reduced fat deposition, and enhanced muscle growth. Developed by Elanco Animal Health (formerly part of Eli Lilly and Company), it is approved for use in several countries but banned or restricted in many others due to safety concerns[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ractopamine.